COMMENTARY: understanding the benefits of pediatric anti-retroviral treatment in resource-limited settings.
Access to antiretroviral treatment in resource-limited settings has repeatedly demonstrated reduction in mortality. With more treatment options becoming available, the ability to optimize therapy will depend on population-specific clinical trial data. The role of nondrug factors for optimizing therapy and the potential for drug-related adverse events that are population-specific should not be underestimated.
Hetherington
Seth
S
Icagen, Inc., Durham, NC. shetherington@icagen.com
D044966:Anti-Retroviral Agents / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D003906:Developing Countries; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D006295:Health Resources; D006801:Humans
D044966:Anti-Retroviral Agents